United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Tredje AP fonden

Tredje AP fonden lessened its stake in United Therapeutics Co. (NASDAQ:UTHR) by 50.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,680 shares of the biotechnology company’s stock after selling 4,679 shares during the period. Tredje AP fonden’s holdings in United Therapeutics were worth $1,651,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in UTHR. Victory Capital Management Inc. increased its position in United Therapeutics by 21.9% in the 3rd quarter. Victory Capital Management Inc. now owns 186,819 shares of the biotechnology company’s stock valued at $66,947,000 after acquiring an additional 33,599 shares during the period. Oppenheimer & Co. Inc. increased its position in United Therapeutics by 20.9% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 6,248 shares of the biotechnology company’s stock valued at $2,239,000 after acquiring an additional 1,078 shares during the period. Archer Investment Corp acquired a new position in United Therapeutics in the 3rd quarter valued at about $283,000. Nicollet Investment Management Inc. increased its position in United Therapeutics by 1.1% during the 3rd quarter. Nicollet Investment Management Inc. now owns 5,833 shares of the biotechnology company’s stock worth $2,090,000 after purchasing an additional 61 shares during the period. Finally, Seizert Capital Partners LLC increased its position in United Therapeutics by 59.2% during the 3rd quarter. Seizert Capital Partners LLC now owns 38,906 shares of the biotechnology company’s stock worth $13,942,000 after purchasing an additional 14,465 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of the stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This represents a 4.41 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $360.76, for a total value of $3,607,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $929,678.52. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 116,464 shares of company stock valued at $42,396,244. 11.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. UBS Group boosted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Stock Performance

UTHR stock opened at $307.24 on Friday. United Therapeutics Co. has a 1 year low of $221.53 and a 1 year high of $417.82. The stock’s 50 day moving average price is $349.77 and its 200 day moving average price is $358.48. The firm has a market cap of $13.80 billion, a P/E ratio of 13.49, a PEG ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same quarter in the prior year, the company earned $4.36 EPS. On average, research analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.